

Jacques Descotes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11971950/publications.pdf>

Version: 2024-02-01

62
papers

2,270
citations

201575

27
h-index

214721

47
g-index

68
all docs

68
docs citations

68
times ranked

1998
citing authors

#	ARTICLE	IF	CITATIONS
1	Translational immunologic safety evaluation: A perspective. <i>Journal of Immunotoxicology</i> , 2013, 10, 83-89.	0.9	2
2	Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status. <i>Resuscitation</i> , 2013, 84, 384-390.	1.3	10
3	Sudden Death of Cardiac Origin and Psychotropic Drugs. <i>Frontiers in Pharmacology</i> , 2012, 3, 76.	1.6	30
4	Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: Role of myocyte structure and myocardial perfusion. <i>Resuscitation</i> , 2011, 82, 1092-1099.	1.3	17
5	A9 Immune response in human pathology: Hypersensitivity and autoimmunity. , 2011, , 139-149.		1
6	Pregnancy outcome after risk assessment of occupational exposure to organic solvents: A prospective cohort study. <i>Reproductive Toxicology</i> , 2010, 30, 409-413.	1.3	10
7	Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia. <i>International Journal of Toxicology</i> , 2010, 29, 435-466.	0.6	66
8	Use of Contact Hypersensitivity in Immunotoxicity Testing. <i>Methods in Molecular Biology</i> , 2010, 598, 233-239.	0.4	1
9	Immunotoxicity of monoclonal antibodies. <i>MAbs</i> , 2009, 1, 104-111.	2.6	119
10	Target Sites. , 2009, , 451-455.		0
11	Trimetazidine Protective Effect Against Ischemia-Induced Susceptibility to Ventricular Fibrillation in Pigs. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 29-36.	1.3	10
12	Clinical immunotoxicity of therapeutic proteins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1537-1549.	1.5	68
13	Ivabradine Induces an Increase in Ventricular Fibrillation Threshold During Acute Myocardial Ischemia: An Experimental Study. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 548-554.	0.8	27
14	Flu-Like Syndrome and Cytokines. <i>Methods in Pharmacology and Toxicology</i> , 2007, , 193-204.	0.1	12
15	Clinical Adverse Effects of Cytokines on the Immune System. <i>Methods in Pharmacology and Toxicology</i> , 2007, , 319-348.	0.1	5
16	Methods of evaluating immunotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 249-259.	1.5	70
17	Acute Occupational Poisoning By Octogen: First Case Report. <i>Clinical Toxicology</i> , 2006, 44, 189-190.	0.8	4
18	The effects of ropivacaine at clinically relevant doses on myocardial ischemia in pigs. <i>Journal of Anesthesia</i> , 2006, 20, 341-343.	0.7	7

#	ARTICLE	IF	CITATIONS
19	Toxicovigilance: A new approach for the hazard identification and risk assessment of toxicants in human beings. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 599-603.	1.3	30
20	Popliteal lymph node assay: facts and perspectives. <i>Journal of Applied Toxicology</i> , 2005, 25, 451-458.	1.4	33
21	The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop. <i>Journal of Immunotoxicology</i> , 2005, 2, 61-83.	0.9	53
22	Role of natural killer cells in immunotoxicity: an update. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 603-608.	1.3	7
23	Immune response in human pathology: hypersensitivity and autoimmunity. , 2005, , 117-127.		0
24	Evaluation of a Lymph Node Proliferation Assay for its Ability to Detect Pharmaceuticals with Potential to Cause Immune-Mediated Drug Reactions. <i>Journal of Immunotoxicology</i> , 2005, 2, 11-20.	0.9	40
25	Immunotoxicology. <i>Drug Safety</i> , 2005, 28, 127-136.	1.4	48
26	Clinical and histopathological progression of lesions in lupus-prone (NZB/NZW) F1 mice. <i>Experimental and Toxicologic Pathology</i> , 2004, 56, 37-44.	2.1	25
27	Cytokine release does not improve the sensitivity and specificity of the direct popliteal lymph node assay. <i>Toxicology</i> , 2004, 200, 247-254.	2.0	11
28	Popliteal lymph node responses to acetone and ethanol differ from those induced by streptozotocin. <i>Archives of Toxicology</i> , 2004, 78, 649-654.	1.9	8
29	Importance of immunotoxicity in safety assessment: a medical toxicologist's perspective. <i>Toxicology Letters</i> , 2004, 149, 103-108.	0.4	46
30	Hidden Cardiac Lesions and Psychotropic Drugs as a Possible Cause of Sudden Death in Psychiatric Patients: A Report of 14 Cases and Review of the Literature. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 100-105.	0.9	26
31	Autoimmune diseases and vaccinations. <i>European Journal of Dermatology</i> , 2004, 14, 86-90.	0.3	23
32	Immunosuppressive drugs and cancer. <i>Toxicology</i> , 2003, 185, 229-240.	2.0	176
33	NK-cell activity in immunotoxicity drug evaluation. <i>Toxicology</i> , 2003, 185, 241-250.	2.0	37
34	From clinical to human toxicology: linking animal research and risk assessment in man. <i>Toxicology Letters</i> , 2003, 140-141, 3-10.	0.4	23
35	Allergic adverse reactions to sulfonamides. <i>Current Allergy and Asthma Reports</i> , 2002, 2, 16-25.	2.4	84
36	Drug allergy diagnosis in humans: possibilities and pitfalls. <i>Toxicology</i> , 2001, 158, 1-10.	2.0	34

#	ARTICLE	IF	CITATIONS
37	Gell and Coombs's classification: is it still valid?. <i>Toxicology</i> , 2001, 158, 43-49.	2.0	116
38	Compared effects of morphine and nickel chloride on NK cell activity in vitro in rats and monkeys. <i>Journal of Applied Toxicology</i> , 2001, 21, 431-434.	1.4	28
39	Responses of the Immune System to Injury. <i>Toxicologic Pathology</i> , 2000, 28, 479-481.	0.9	35
40	Autoimmunity and toxicity testing. <i>Toxicology Letters</i> , 2000, 112-113, 461-465.	0.4	28
41	Occupational toxic risks in dental laboratory technicians. <i>Journal of Environmental Medicine</i> , 1999, 1, 307-314.	0.2	9
42	Treatment of Drug-Induced Agranulocytosis with Haematopoietic Growth Factors. <i>BioDrugs</i> , 1999, 11, 185-200.	2.2	18
43	Antibiotic-Associated Hepatitis: Update from 1990. <i>Annals of Pharmacotherapy</i> , 1997, 31, 204-220.	0.9	51
44	Acute Hexogen Poisoning After Occupational Exposure. <i>Journal of Toxicology: Clinical Toxicology</i> , 1996, 34, 109-111.	1.5	23
45	Drugs acting on the immune system. <i>Side Effects of Drugs Annual</i> , 1995, , 334-368.	0.6	1
46	Clinical Toxicity of Cytokines Used As Haemopoietic Growth Factors. <i>Drug Safety</i> , 1995, 13, 371-406.	1.4	121
47	Clinical Toxicity of the Interferons. <i>Drug Safety</i> , 1994, 10, 115-150.	1.4	238
48	Morphology of popliteal lymph node responses in brown Norway rats. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1994, 41, 95-108.	1.1	22
49	Lymphocyte activation by liposome-trapped streptozotocin in murine popliteal lymph node (PLN) test. <i>International Journal of Immunopharmacology</i> , 1994, 16, 817-824.	1.1	6
50	Anaphylaxis models in the guinea-pig. <i>Toxicology</i> , 1994, 93, 55-61.	2.0	51
51	Contact sensitization assays in guinea-pigs: are they predictive of the potential for systemic allergic reactions?. <i>Toxicology</i> , 1994, 93, 63-75.	2.0	19
52	Chemical Structure and Safety of Spiramycin. <i>Drug Investigation</i> , 1993, 6, 43-48.	0.6	4
53	Immunomodulating agents. <i>Side Effects of Drugs Annual</i> , 1993, 17, 432-435.	0.6	0
54	Cefaclor-Associated Serum Sickness-Like Disease: Eight Cases and Review of the Literature. <i>Annals of Pharmacotherapy</i> , 1992, 26, 910-914.	0.9	66

#	ARTICLE	IF	CITATIONS
55	Clinical Toxicity of Interleukin-2. Drug Safety, 1992, 7, 417-433.	1.4	88
56	Activation of CD4+ and CD8+ lymphocyte subsets by streptozotocin in murine popliteal lymph node (PLN) test. Journal of Autoimmunity, 1992, 5, 183-197.	3.0	60
57	Spiramycin: safety in man. Journal of Antimicrobial Chemotherapy, 1988, 22, 207-210.	1.3	18
58	Immunotoxicology: health aspects and regulatory issues. Trends in Pharmacological Sciences, 1986, 7, 1-3.	4.0	10
59	Immunomodulating Agents and Hepatic Drug-Metabolizing Enzymes. Drug Metabolism Reviews, 1985, 16, 175-184.	1.5	31
60	Adverse Consequences of Chemical Immunomodulation. Clinical Research Practices and Drug Regulatory Affairs, 1985, 3, 45-52.	0.0	13
61	Pharmacokinetic drug interactions with macrolide antibiotics. Journal of Antimicrobial Chemotherapy, 1985, 15, 659-664.	1.3	39
62	Safety Assessment Studies: Immunotoxicity. , 0, , 269-321.		0